A study to assess real incidence of thrombotic events in cancer patients treated with antiangiogenic drugs (bevacizumab, ramucirumab, pazopanib, sorafenib and sunitinib)
Latest Information Update: 15 Oct 2020
At a glance
- Drugs Bevacizumab (Primary) ; Pazopanib (Primary) ; Ramucirumab (Primary) ; Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Cancer
- Focus Pharmacodynamics
- 15 Oct 2020 New trial record
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress